Next Article in Journal
1H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
Next Article in Special Issue
mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
Previous Article in Journal
In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression
Previous Article in Special Issue
Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity
Open AccessReview

Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers

1
Leukemic Niche and Oxidative metabolism (LNOx), CNRS ERL 7001, University of Tours, 37000 Tours, France
2
Innovation Moléculaire et Thérapeutique (IMT), EA 7501, University of Tours, 37000 Tours, France
3
Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(1), 240; https://doi.org/10.3390/cancers12010240
Received: 6 December 2019 / Revised: 10 January 2020 / Accepted: 13 January 2020 / Published: 18 January 2020
(This article belongs to the Special Issue Targeting STAT3 and STAT5 in Cancer)
Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors of cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated in hematopoietic cancers. STAT3 and STAT5 are common targets for different tyrosine kinase oncogenes (TKOs). In addition, STAT3 and STAT5 proteins were shown to contain activating mutations in some rare but aggressive leukemias/lymphomas. Both proteins also contribute to drug resistance in hematopoietic malignancies and are now well recognized as major targets in cancer treatment. The development of inhibitors targeting STAT3 and STAT5 has been the subject of intense investigations during the last decade. This review summarizes the current knowledge of oncogenic STAT3 and STAT5 functions in hematopoietic cancers as well as advances in preclinical and clinical development of pharmacological inhibitors. View Full-Text
Keywords: STAT3; STAT5; hematopoietic cancers; therapeutic targeting; pharmacological inhibitors STAT3; STAT5; hematopoietic cancers; therapeutic targeting; pharmacological inhibitors
Show Figures

Figure 1

MDPI and ACS Style

Brachet-Botineau, M.; Polomski, M.; Neubauer, H.A.; Juen, L.; Hédou, D.; Viaud-Massuard, M.-C.; Prié, G.; Gouilleux, F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers 2020, 12, 240. https://doi.org/10.3390/cancers12010240

AMA Style

Brachet-Botineau M, Polomski M, Neubauer HA, Juen L, Hédou D, Viaud-Massuard M-C, Prié G, Gouilleux F. Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers. Cancers. 2020; 12(1):240. https://doi.org/10.3390/cancers12010240

Chicago/Turabian Style

Brachet-Botineau, Marie; Polomski, Marion; Neubauer, Heidi A.; Juen, Ludovic; Hédou, Damien; Viaud-Massuard, Marie-Claude; Prié, Gildas; Gouilleux, Fabrice. 2020. "Pharmacological Inhibition of Oncogenic STAT3 and STAT5 Signaling in Hematopoietic Cancers" Cancers 12, no. 1: 240. https://doi.org/10.3390/cancers12010240

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop